کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
11033436 1615013 2018 25 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Repurposing of dexpramipexole to treatment of neonatal hypoxic/ischemic encephalopathy
ترجمه فارسی عنوان
تجویز دگزاپرمیپکسول به درمان آنسفالوپاتی هیپوکسمی نوزاد / مجاری اسهالی
کلمات کلیدی
دگزاپاریم پیکسول، آنسفالوپاتی ایسکمیک-هیپوکسیک، موش صحرایی محافظت از عصب
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی علوم اعصاب (عمومی)
چکیده انگلیسی
Dexpramipexole (DEX) is a drug with a good safety profile in humans, known for its ability to increase mitochondrial ATP production and prompt neuroprotection in adult rodents subjected to cerebral ischemia. In the present study we evaluated the effect of DEX in rat pups subjected to common carotid artery occlusion plus hypoxia (CCAoH, the classic Rice-Vannucci model). Because of the wide range of infarct size distribution in the CCAoH model, a priori subanalysis based on the effect of DEX on mild/moderate or severe brain injuries was conducted. The subanalysis showed that the drug (3 mg/kg bid i.p, after the hypoxic insult) decreased the infarction size in pups with mild/moderate injuries. Next, we developed a distal middle cerebral artery occlusion plus hypoxia (dMCAoH) model, characterized by an intra-experimental infarct size variability lower than that of the CCAoH model. Post-ischemic treatment with DEX (3 mg/kg bid i.p, after the hypoxic insult) reduced brain infarcts in pups exposed to dMCAoH. For the first time, we show that DEX reduces brain injury in different models of neonatal HIE. In light of the favorable safety profile of DEX in humans, the drug might have a realistic translational potential to treatment of perinatal cerebrovascular disorders.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Neuroscience Letters - Volume 687, 20 November 2018, Pages 234-240
نویسندگان
, , , , ,